<!DOCTYPE html>
<html>
<head>
<title>12_1_MASTER_ALEXION_P03_T05_S02</title>
<meta name="viewport" content="user-scalable=no, width=device-width, initial-scale=1.0, maximum-scale=1.0"/>
<meta name="apple-mobile-web-app-capable" content="yes" />
<meta name="format-detection" content="telephone=no" />


<link href="../global/css/font.css" type="text/css" rel="stylesheet">
<link href="../global/css/global.css" type="text/css" rel="stylesheet">
<link href="css/main.css" type="text/css" rel="stylesheet">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head>
<body>
	<div id="container">
        <!--end elements-->
        <div id="main_container" class="bg_orange">
           	<div class="claim">
				<i18n id='claim'>
					The balanced approach that helps<br>
					improve upper-GI<sup>§</sup> tolerability.<sup>†</sup>
				</i18n>
			</div>
			<div class='vivimo_effect1 Helvetica_Round_Bold orange flyer'>
				<i18n id='vivimo_effect1'>
					VIMOVO provides effective<br>
					gastroprotection with<br>
					a built in PPI.<sup>Ł,1,2</sup>
				</i18n>
			</div>
			<div class='vivimo_line flyer'></div>
			<div class='vivimo_effect2'>
				<div id='eighttwopercent' class='brown Helvetica_Round_Bold'>
					<i18n id='eighttwopercent'>
						82%
					</i18n>
				</div>
				<div id='vivimo_risk' class='grey'>	
					<span>
						<i18n id='v2_vivimo_risk1'>
							relative risk reduction<br>in endoscopic gastric<br>ulcer over 6 months<sup>1</sup>
						</i18n>
					</span><br><br>
					<span>
						<i18n id='vivimo_risk2'>
							VIMOVO patients experienced significantly fewer NSAID-related gastric ulcers vs patients receiving EC naproxen over 6 months.<br>
							Absolute risk reduction was 19% at 6 months VIMOVO vs EC naproxen.<sup>2</sup>				
						</i18n>
					</span>
				</div>
			</div>
			
			<div class='graph flyer'>
				<div class='graph_month'>
					<div>
						<i18n id='graph_month1'>
							Month 1
						</i18n>				
					</div>
					<div>
						<i18n id='graph_month2'>
							Month 3
						</i18n>				
					</div>
					<div>
						<i18n id='graph_month3'>
							Month 6
						</i18n>				
					</div>
				</div>			
			</div>
			<div class='graph_legend'>
				<div class='graph_legend1'>
					<i18n id='graph_legend1'>
						<span class='HelveticaLTStd_Roman blue'>VIMOMO</span> (n = 218)<br>
						500mg<br>
						<span class='HelveticaLTStd_Roman'>EC naproxen (n = 216)</span><br>
						500mg
					</i18n>				
				</div>				
				<div class='graph_legend2'>
					<i18n id='graph_legend2'>
						*p < 0.001<br>
						Month 1, 3, 6 vs placebo
					</i18n>				
				</div>				
			</div>
			<div class='graph_vertical HelveticaLTStd_Roman'>
				<i18n id='v2graph_vertical'>
					% of Patients (≤ 50 or with a history of peptic ulceration)<br>
					discontinuing therapy due to upper-GI issues. OA, RA, AS and other<br>
					patients requiring daily NSAID. Pooled analysis, Studies 301 and 302
				</i18n>				
			</div>
        </div>	
        <!--End #main_container -->
		
		<!-- Ref -->
		<div class="ref_wrapper" id="S017_ref_all"></div>	
        <div id="scroll-wrapper" class="scroll_ref">
			<div id="scroller">	
                <h1 class="brown Helvetica_Round_Bold"><i18n id="S017_ref">References:</i18n></h1>
                
				<div class="ref HelveticaLTStd_Roman">
               		<span class="ref_number">1.</span>
                	<i18n id="S017_ref_txt0">VIMOVO Summary of Product Information.</i18n>
                </div>	
				
                <div class="ref HelveticaLTStd_Roman">
               		<span class="ref_number">2.</span>
                	<i18n id="S017_ref_txt1">Goldstein, JL, et al. <span class='HelveticaNeueLTStd_it'>Aliment Pharmacol Ther</span> 2010; 32(3): 401-413.</i18n>
                </div>
                
				<div class="ref HelveticaLTStd_Roman">
					<span class="ref_number">§&nbsp;</span>
                    <i18n id="S017_ref_txt3">
						Gastrointestinal
                    </i18n>
				</div>  <!--end Ref-->
                
                <div class="ref HelveticaLTStd_Roman">
					<span class="ref_number">Ł&nbsp;</span>
                    <i18n id="S017_ref_txt4">
						Proton pump inhibitor
                    </i18n>
				</div>  <!--end Ref-->
                
                <div class="ref HelveticaLTStd_Roman">
					<span class="ref_number">†&nbsp;</span>
                    <i18n id="S017_ref_txt5">
						Helping to improve upper-GI tolerability is evidenced by fewer upper-GI ulcers, fewer discontinuations due to upper-GI AEs including duodenal ulcers, and less abdominal discomfort over a 6-month period as measured by dyspepsia symptoms versus EC naproxen.
					</i18n>
				</div>  <!--end Ref-->
				<!--end Ref-->
			</div>
            <div class="close"><span class="right"></span></div>
            <div class="arrow_ref"></div>
		</div>
		<!-- End ref -->
		
        <div class="info_wrapper" id="info_all"></div>	
		<div id="scroll-wrapper" class="scroll_info">
			<div id="scroller">	
				<h1 class="brown Helvetica_Round_Bold"><i18n id="S017_info">Study Design:</i18n></h1>
                
				<div class="ref HelveticaLTStd_Roman">
                    <i18n id="v2_S017_info1">
						Study 301 was a 6-month randomized, double-blind, multi-center
						study in patients (stratified by low-dose aspirin ≤ 325mg use) with
						OA, RA or AS, or chronic musculoskeletal conditions requiring
						ongoing NSAID therapy, at risk of GI toxicity from daily NSAID use.
						Patients aged ≥ 50 years or 18-49 years with a history of ulcer were
						randomized to either VIMOVO 500/20mg or EC naproxen 500mg
						twice daily. The primary endpoint was cumulative incidence of
						endoscopic gastric ulcers, over 6 months. Study 302 was of similar
						design.<sup>2</sup>
					</i18n>
				</div>  <!--end info-->
				
			</div>
            <div class="close"><span class="right"></span></div>
            <div class="arrow_info"></div>
		</div>
		<!-- End info -->
     </div>
   </body>     
       <script type="text/javascript" src="../global/js/config.js"></script>
    <script type='text/javascript' src='../framework/steal/steal.production.js?../framework,development'></script>
	
	<script src="resource:js/SystemBridge.js"></script>
	<script type="text/javascript" src="../global/js/havie.js"></script>
    <script type="text/javascript" src="../global/js/global.js"></script>
    <script type="text/javascript" src="../global/js/ref.js"></script>
    <script type="text/javascript" src="javascript/main.js"></script>	
</html>